Growth Metrics

Vivos (RDGL) Capital Expenditures (2010 - 2017)

Vivos recorded quarterly Capital Expenditures of $2800.0 in Q1 2017, down 71.29% quarter-over-quarter from $9754.0 in Q1 2013.

Vivos' Capital Expenditures history runs 4 years deep, the most recent figure standing at $2800.0 for Q1 2017.

  • In Q1 2017, Capital Expenditures changed N/A year-over-year to $2800.0; the TTM figure through Mar 2017 stood at -$72124.0 (changed N/A YoY), while the FY2025 annual figure was $103185.0, changed N/A from the prior year.
  • Capital Expenditures came in at $2800.0 for Q1 2017 at Vivos, down from $9754.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $9754.0 in Q1 2013 to a low of $2800.0 in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 399.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn 166.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn 444.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn 177.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn 64.90 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -85.46 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 76.60 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 86.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 90.20 Mn
10 Vivos - - -3,105.00 -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2017 2,800.00
Mar 31, 2017 2,800.00
Mar 31, 2013 9,754.00
Mar 31, 2013 9,754.00
Dec 31, 2012 -84,678.00
Dec 31, 2012 -84,678.00
Dec 31, 2010 28,690.00
Dec 31, 2010 28,690.00